Panion Animal Health AB invites all interested persons to an investor meeting at Mangolds offices, Engelbrektsplan 2, Stockholm on Friday the 14th of December 2018 from 12 – 13.

The occasion for the meeting is to provide information to current and new investors in relation to the share issue that runs from December 7, 2018 – December 21, 2018. The meeting is free and open for everyone.

Panion’s CEO, Anja Holm, will present Panion’s business plans and the ongoing research in gene therapy against epilepsy in dogs. The results that have been obtained over the past two years of Panion’s existence will be highlighted. The future development plans and expected milestones for the epilepsy product, and Panion’s work on potential new in-licensing projects, will be discussed. The motive for the share issue is to secure the upcoming clinical pilot study in USA. There are currently different options available for future financing. By offering the current shareholders the opportunity to participate, we give the existing owners the same terms as may be offered to external investors.

To register for the investor meeting, please email to emissionstjanster@mangold.se

—————————-
Panions VD, Anja Holm, kommer den 14 december hålla en investerarträff i Mangolds lokaler i Stockholm.

Anja kommer redogöra för Panions verksamhet och pågående forskning inom genterapi för behandling av epilepsiliknande tillstånd hos hundar.

För anmälan till investerarträffen vänligen maila till emissionstjanster@mangold.se

Pressrelease >>